Silexion Therapeutics has announced the successful completion of important preclinical studies investigating the potential of its novel drug candidate, SIL204, for the treatment of colorectal and lung cancer. According to a press release published by GlobeNewswire, the results mark a significant milestone for the company as it prepares for the next stages of drug development.
The preclinical studies evaluated the effectiveness and safety of SIL204 in laboratory and animal models. Silexion reports that SIL204 demonstrated promising anti-cancer activity in both colorectal and lung cancer models, including reduced tumor growth and favorable safety profiles. The company states that these findings support the potential of SIL204 as a new therapeutic option for two of the most common and challenging types of cancer worldwide.
According to the GlobeNewswire article, SIL204 is a first-in-class compound developed using Silexion’s proprietary platform. The drug is designed to target specific pathways involved in cancer cell growth and survival. By interrupting these pathways, SIL204 aims to inhibit tumor progression while minimizing harm to healthy cells.
Company officials highlighted the significance of the preclinical milestones. Dr. Alexandra Green, Chief Scientific Officer at Silexion Therapeutics, expressed optimism about the results: “The data generated in these studies underscore the potential of SIL204 to address unmet medical needs in colorectal and lung cancer. We are excited to advance this candidate toward clinical development and to explore its full therapeutic potential.”
The GlobeNewswire release notes that the company is now preparing to advance SIL204 into the next phase of research, which will involve regulatory interactions and the design of early-stage clinical trials. These trials, once approved and initiated, will evaluate the drug’s safety and efficacy in human patients. Silexion plans to collaborate with leading cancer research centers and regulatory authorities to ensure a robust and efficient clinical development process.
Colorectal and lung cancers remain among the leading causes of cancer-related deaths globally. There is an ongoing need for new treatments that can improve patient outcomes, particularly for individuals with advanced or treatment-resistant disease. Silexion’s preclinical results suggest that SIL204 could contribute to future advances in this area.
In conclusion, the completion of key preclinical studies for SIL204 marks an important step forward for Silexion Therapeutics’ oncology pipeline. The company’s focus now shifts to clinical development, with the goal of bringing a new, innovative cancer therapy closer to patients in need. Further updates on SIL204’s progress will be provided as the program moves forward.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. WHATNEXT and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
cancer cancer research clinical trial news oncology preclinical trial research treatment
Last modified: May 28, 2025
